Eosinophilic Granulomatosis with Polyangiitis (Asthma Phase) Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub as a member
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Eosinophilic Granulomatosis with Polyangiitis (Asthma Phase)
Eosinophilic Granulomatosis with Polyangiitis (EGPA), particularly its asthma phase, is a rare and challenging autoimmune condition. Often starting as severe asthma, it can progress to affect various organs. Managing EGPA involves ongoing treatment, which can be costly. TheDrugClub helps ease this financial burden, making essential medications more affordable for our members.
Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare autoimmune disease characterized by inflammation of small-to-medium-sized blood vessels (vasculitis) and an overabundance of eosinophils, a type of white blood cell. For many, the condition begins with an "asthma phase," where individuals experience severe, difficult-to-control asthma that often develops in adulthood. This phase can also include allergic rhinitis, sinusitis, and nasal polyps, making it seem like a worsening of typical allergic conditions.
As EGPA progresses, it can affect various organ systems, including the nerves, skin, heart, and kidneys, leading to a range of symptoms from nerve pain and skin rashes to more serious organ damage. Early diagnosis and consistent management are crucial to control symptoms and prevent further complications. While the exact cause of EGPA is unknown, it's believed to involve a combination of genetic and environmental factors.
Treatment for EGPA primarily focuses on controlling inflammation and suppressing the immune system. Corticosteroids, such as prednisone, are often the first line of defense to manage acute flares and reduce eosinophil counts. For long-term control and to reduce corticosteroid dependence, immunosuppressants like azathioprine, methotrexate, or cyclophosphamide may be prescribed. In cases of severe or refractory disease, biologic medications, such as mepolizumab or benralizumab, which target eosinophils, have shown significant benefit. These treatments, while vital, often come with a substantial price tag, creating an additional challenge for patients and their families.
This is where TheDrugClub steps in. As a prescription savings membership program, we are
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.